

# **Certificate of Analysis**

Print Date: Oct 12th 2022

www.tocris.com

Product Name: AZ 12799734 Catalog No.: 6870 Batch No.: 1

CAS Number: 1117684-36-2

IUPAC Name: 4-[[4-[(2.6-Dimethyl-3-pyridinyl)oxy]-2-pyridinyl]amino]benzenesulfonamide

## 1. PHYSICAL AND CHEMICAL PROPERTIES

**Batch Molecular Formula:** C<sub>18</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub>S

Batch Molecular Weight: 370.43

Physical Appearance: White solid

Solubility: DMSO to 100 mM Storage: Store at -20°C

**Batch Molecular Structure:** 

## 2. ANALYTICAL DATA

HPLC: Shows 100.0% purity

<sup>1</sup>H NMR: Consistent with structure

Mass Spectrum: Consistent with structure

Microanalysis: Carbon Hydrogen

Carbon Hydrogen Nitrogen

Theoretical 58.36 4.9 15.12 Found 58.26 4.92 15.12

529449 www.tocris.com/distributors Tel:+1 612 379 2956



## **Product Information**

Print Date: Oct 12th 2022

www.tocris.com

Product Name: AZ 12799734 Catalog No.: 6870 1

CAS Number: 1117684-36-2

IUPAC Name: 4-[[4-[(2.6-Dimethyl-3-pyridinyl)oxy]-2-pyridinyl]amino]benzenesulfonamide

### **Description:**

AZ 12799734 is a potent inhibitor of transforming growth factor- $\beta$  type I receptor (TGF- $\beta$ RI; ALK5) (IC $_{50}$  = 17 nM in cellular inhibition assay and 47 nM in TGF- $\beta$ -induced luciferase activity assay). Also inhibits ALK4, ALK6 and ALK7 at concentrations under 10  $\mu$ M. Inhibits BMP signaling, phosphorylation of SMAD1 and SMAD2, and TGF- $\beta$ -induced epithelial cell migration in vitro. Displays cardiotoxicity in vivo. Orally bioavailable.

#### **Physical and Chemical Properties:**

Batch Molecular Formula:  $C_{18}H_{18}N_4O_3S$ Batch Molecular Weight: 370.43

Physical Appearance: White solid

Minimum Purity: ≥98%

## **Batch Molecular Structure:**

Storage: Store at -20°C

## Solubility & Usage Info:

DMSO to 100 mM

#### Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

#### References:

**Spender** *et al* (2019) Preclinical evaluation of AZ12601011 and AZ12799734, inhibitors of transforming growth factor β superfamily type 1 receptors. Mol.Pharmacol. *95* 222. PMID: 30459156.

Anderton et al (2011) Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol.Pathol. 39 916. PMID: 21859884.

**Goldberg** *et al* (2009) Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5). J.Med.Chem. *52* 7901. PMID: 19736928.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use